Charles Bankhead

News, features, and commentary about cancer-related issues

Significant impact on RFS with subtotal resection, and molecular analysis suggests hypoxic effect

Big Comeback for Myeloma Drug; DIY Cancer Therapy; Gut Clues to Bladder Cancer

Complete responses in 21% of patients treated with single-agent revumenib

Low rate of recurrence with surgery or nonsurgical options, but data can inform decisions

Confirmed responses in one-fourth to one-third of patients with refractory disease

Valeda photobiomodulation system slowed disease progression and improved vision

A look back at some of the newsworthy developments of 2024

Large cohort study showed cancer risk increased with exposure to fine particulate matter

Blood Test for CRC Screening Lags Behind Other Options in Cost-Effectiveness Study

Precision Medicine Approach Shows Promise for Anaplastic Thyroid Cancer

Personalized Breast Cancer Treatment; Insights Into HPV in Men; Exercise and Cancer

Significant improvement beyond 100 weeks after single injection of mutation-agnostic MCO-010

Study suggests potential to eliminate a third of in-office visits without harming care

Absolute risk remains low, however

Radioligand Shows Promise in Metastatic Hormone-Sensitive Prostate Cancer

Low rates of toxicity and salvage cystectomy, with 2-year survival similar to surgery

Osimertinib plus ramucirumab in first line shows 9-month PFS advantage over EGFR inhibition alone

Adding inavolisib to palbociclib/fulvestrant more than doubled PFS in endocrine-resistant disease

News, features, and commentary about cancer-related issues